Active	Status	Sponsor type	Region	Phase	Filter
14 Active 1 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

14 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Frank, Samuel
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease First biomarker data from trial for Huntington’s disease Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease Safety data from P1/2 trial for Huntington’s disease Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease	Recruiting	1/2	37	US	intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery	UniQure Biopharma B.V.	Huntington's Disease	04/29	06/29
vUHDRS, NCT05748288: Development of the Virtual Unified Huntington's Disease Rating Scale	Completed	N/A	60	US		Huntington Study Group	Huntington Disease	05/23	05/23
NCT06219629: Parkinson's Disease Progression Study	Recruiting	N/A	70	US		Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals	Parkinson Disease	08/25	09/25
MET, NCT05287711: Adjunctive Motivational Alcohol Intervention to Prevent IPV	Recruiting	N/A	300	US	Motivational Enhancement Therapy, MET, Alcohol Education Control, AE, Treatment as Usual, TAU, Strength at Home, SAH	VA Office of Research and Development	Alcohol Use and Intimate Partner Violence	09/27	09/27
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62
Moukheiber, Emile
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33
Schneider, Ruth
Generate-Boost, NCT03993262: Trial to Evaluate Efficacy and Safety of Bortezomib in Patients with Severe Autoimmune Encephalitis	Recruiting	2	50	Europe	Bortezomib, Placebo, isotonic NaCl solution	Jena University Hospital, Federal Ministry of Education and Reserach (BMBF)	Autoimmune Encephalitis	11/25	04/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
OPAL, NCT05287620: Objective, Passive Assessment of LRRK2 Carriers	Completed	N/A	10	US	Emerald device	University of Rochester, Emerald Innovations, Michael J. Fox Foundation for Parkinson's Research	Parkinson Disease	05/24	05/24
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33